# COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)

> **NCT04367402** · — · UNKNOWN · sponsor: **Azienda Ospedaliera San Paolo** · enrollment: 600 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **OTHER:** BioMedomics COVID-19 IgM-IgG Rapid Test

## Key facts

- **NCT ID:** NCT04367402
- **Lead sponsor:** Azienda Ospedaliera San Paolo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-30
- **Primary completion:** 2020-04-24
- **Final completion:** 2020-09
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2020-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04367402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04367402, "COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04367402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*